EXHIBIT A


                       GIVEN IMAGING ANNOUNCES STRUCTURED
                           TRADING PLAN FOR PRESIDENT

Yoqneam, Israel. (August 6, 2002) - Given Imaging Ltd. (NASDAQ: GIVN) announced
today that Dr. Gavriel Meron, President and Chief Executive Officer, has entered
into a structured trading plan under SEC Rule 10b5-1 to sell up to an aggregate
of 104,000 ordinary shares of Given Imaging. Sales under the plan will take
place on a weekly basis for a period of up to approximately one year, subject to
minimum share prices during that period.

Dr. Meron founded Given Imaging in January 1998 and since the commencement of
his employment over four years ago, he has not sold any shares in the company.
Proceeds from sales will be used to repay a $200,000 loan received by Dr. Meron
from the company in 2001 upon receipt of clearance from the FDA for the Given
System, and to enable him to diversify his holdings. The shares that may be sold
under the plan represent less than 15% of Dr. Meron's total shares and vested
and unvested options in the company.

Rule 10b5-1 allows corporate insiders to establish prearranged written plans to
buy or sell a specified number of shares of company stock over a predetermined
period of time. Insiders may adopt such plans when they are not in possession of
material nonpublic information in order to diversify their investment portfolio
while minimizing the market effect of stock sales or purchases by spreading them
out over an extended period of time and to avoid concerns about initiating stock
transactions while in possession of material nonpublic information. The Board of
Directors of Given Imaging has adopted guidelines permitting officers of the
company to enter into such plans.

About Given Imaging

Given Imaging produces and markets the Given Diagnostic System, which features
the M2A(R) Capsule Endoscope, a fundamentally new approach to examining the
gastrointestinal tract. The system uses a disposable miniature video camera
contained in a

<PAGE>
capsule that is ingested by a patient and delivers high quality color images in
a painless and noninvasive manner. The test can be conducted while a patient
continues normal daily activities. The system received clearance from the FDA in
August 2001 and received permission to affix the CE mark in May 2001. The system
is currently being marketed in more than 40 countries worldwide, including the
USA, Canada, Europe, Central and South America and Asia. Thousands of patients
suffering from diseases in the small intestine such as Crohn's, celiac disease,
unexplained abdominal pain with diarrhea, polyposis, intestinal tumors, iron
deficiency anemia and obscure bleeding have already benefited from this
innovative technology. For more information, visit www.givenimaging.com.

This press release contains forward-looking statements, including projections
about our business, within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. For example,
statements in the future tense, words such as "anticipates," "estimates,"
"expects," "intends," "plans," "believes," "intends" and words and terms of
similar substance used in connection with any discussion of future operating or
financial performance identify such forward-looking statements. Those
forward-looking statements are not guarantees of future performance and actual
results could differ materially from our current expectations as a result of
numerous factors, including but not limited to the following: changes in
regulatory environment, our success in implementing our sales, marketing and
manufacturing plan, protection and validity of patents and other intellectual
property rights, the impact of currency exchange rates, the effect of
competition by other companies, the outcome of future litigation, the
reimbursement policies for our product from healthcare payors, and other risks
disclosed in our filings with the U.S. Securities Exchange Commission.